Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
Cancer Treatment and Research Communications
|
August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report
Aakash Desai, Sagar Rakshit, Radhika Bansal, et al.
JTO Clinical and Research Reports
|
November 24, 2025
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC
Arthi Sridhar, Aditi Singh, Scott Hansen, et al.
Future Oncology (London, England)
|
March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumors
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
Ugur Sener, Mason Webb, William G Breen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2018
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
Terry L Ng, Derek E Smith, Rao Mushtaq, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
Tina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Journal for Immunotherapy of Cancer
|
April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew S Block, Garth D Nelson, Jun Chen, et al.
Frontiers in Immunology
|
November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma
Douglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Nature Communications
|
February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
Tina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
Cancer Treatment and Research Communications
|
August 2, 2023
Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report
Aakash Desai, Sagar Rakshit, Radhika Bansal, et al.
JTO Clinical and Research Reports
|
November 24, 2025
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLC
Arthi Sridhar, Aditi Singh, Scott Hansen, et al.
Future Oncology (London, England)
|
March 6, 2023
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumors
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, et al.
Journal of Immunotherapy and Precision Oncology
|
February 8, 2024
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma
Ugur Sener, Mason Webb, William G Breen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
December 14, 2018
ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events
Terry L Ng, Derek E Smith, Rao Mushtaq, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma
Tina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Journal for Immunotherapy of Cancer
|
April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial
Matthew S Block, Garth D Nelson, Jun Chen, et al.
Frontiers in Immunology
|
November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
Katherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma
Douglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Nature Communications
|
February 16, 2024
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
Tina J Hieken, Garth D Nelson, Thomas J Flotte, et al.
Page
of 7